Medlive Technology Co., Ltd.

Informe acción SEHK:2192

Capitalización de mercado: HK$6.6b

Medlive Technology Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Liping Tian

Chief Executive Officer (CEO)

CN¥4.8m

Compensación total

Porcentaje del salario del CEO35.8%
Permanencia del CEO11.6yrs
Participación del CEO1.1%
Permanencia media de la direcciónsin datos
Promedio de permanencia en la Junta Directiva6.3yrs

Actualizaciones recientes de la dirección

Recent updates

Investors Shouldn't Be Too Comfortable With Medlive Technology's (HKG:2192) Earnings

Oct 02
Investors Shouldn't Be Too Comfortable With Medlive Technology's (HKG:2192) Earnings

Pinning Down Medlive Technology Co., Ltd.'s (HKG:2192) P/E Is Difficult Right Now

Sep 27
Pinning Down Medlive Technology Co., Ltd.'s (HKG:2192) P/E Is Difficult Right Now

Medlive Technology (HKG:2192) Could Be Struggling To Allocate Capital

Jul 04
Medlive Technology (HKG:2192) Could Be Struggling To Allocate Capital

Medlive Technology Co., Ltd.'s (HKG:2192) Business Is Yet to Catch Up With Its Share Price

Apr 08
Medlive Technology Co., Ltd.'s (HKG:2192) Business Is Yet to Catch Up With Its Share Price

Medlive Technology (HKG:2192) Is Reinvesting At Lower Rates Of Return

Feb 20
Medlive Technology (HKG:2192) Is Reinvesting At Lower Rates Of Return

Are Medlive Technology Co., Ltd. (HKG:2192) Investors Paying Above The Intrinsic Value?

Jan 10
Are Medlive Technology Co., Ltd. (HKG:2192) Investors Paying Above The Intrinsic Value?

Medlive Technology Co., Ltd.'s (HKG:2192) Intrinsic Value Is Potentially 20% Below Its Share Price

Sep 27
Medlive Technology Co., Ltd.'s (HKG:2192) Intrinsic Value Is Potentially 20% Below Its Share Price

Medlive Technology (HKG:2192) Is Reinvesting At Lower Rates Of Return

Jul 10
Medlive Technology (HKG:2192) Is Reinvesting At Lower Rates Of Return

Medlive Technology Co., Ltd. (HKG:2192) Shares Slammed 28% But Getting In Cheap Might Be Difficult Regardless

May 11
Medlive Technology Co., Ltd. (HKG:2192) Shares Slammed 28% But Getting In Cheap Might Be Difficult Regardless

Robust Earnings May Not Tell The Whole Story For Medlive Technology (HKG:2192)

May 02
Robust Earnings May Not Tell The Whole Story For Medlive Technology (HKG:2192)

Results: Medlive Technology Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Mar 26
Results: Medlive Technology Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Here's What's Concerning About Medlive Technology's (HKG:2192) Returns On Capital

Feb 06
Here's What's Concerning About Medlive Technology's (HKG:2192) Returns On Capital

There Are Reasons To Feel Uneasy About Medlive Technology's (HKG:2192) Returns On Capital

Oct 31
There Are Reasons To Feel Uneasy About Medlive Technology's (HKG:2192) Returns On Capital

Medlive Technology (HKG:2192) Could Be Struggling To Allocate Capital

Jul 14
Medlive Technology (HKG:2192) Could Be Struggling To Allocate Capital

These Analysts Just Made A Massive Downgrade To Their Medlive Technology Co., Ltd. (HKG:2192) EPS Forecasts

Apr 03
These Analysts Just Made A Massive Downgrade To Their Medlive Technology Co., Ltd. (HKG:2192) EPS Forecasts

Is Medlive Technology Co., Ltd. (HKG:2192) Worth HK$9.5 Based On Its Intrinsic Value?

Feb 22
Is Medlive Technology Co., Ltd. (HKG:2192) Worth HK$9.5 Based On Its Intrinsic Value?

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Liping Tian en comparación con los beneficios de Medlive Technology?
FechaCompensación totalSalarioIngresos de la empresa
Jun 30 2024n/an/a

CN¥290m

Mar 31 2024n/an/a

CN¥266m

Dec 31 2023CN¥5mCN¥2m

CN¥242m

Sep 30 2023n/an/a

CN¥216m

Jun 30 2023n/an/a

CN¥189m

Mar 31 2023n/an/a

CN¥153m

Dec 31 2022CN¥7mCN¥2m

CN¥117m

Sep 30 2022n/an/a

CN¥83m

Jun 30 2022n/an/a

CN¥48m

Mar 31 2022n/an/a

CN¥44m

Dec 31 2021CN¥7mCN¥1m

CN¥41m

Sep 30 2021n/an/a

CN¥55m

Jun 30 2021n/an/a

CN¥70m

Mar 31 2021n/an/a

CN¥78m

Dec 31 2020CN¥816kCN¥816k

CN¥85m

Dec 31 2019CN¥756kCN¥756k

CN¥31m

Dec 31 2018CN¥736kCN¥736k

CN¥14m

Compensación vs. Mercado: La compensación total de Liping($USD667.63K) está por encima de la media de empresas de tamaño similar en el mercado Hong Kong ($USD481.37K).

Compensación vs. Ingresos: La compensación de Liping ha sido consistente con los resultados de la empresa en el último año.


CEO

Liping Tian (57 yo)

11.6yrs

Permanencia

CN¥4,839,000

Compensación

Ms. Liping Tian is Chairwoman and Chief Executive Officer of Medlive Technology Co. Ltd. Ms. Tian has been Executive Director of Medlive Technology Co. Ltd since April 2013. She has been the executive dire...


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Liping Tian
Chairwoman & CEO11.6yrsCN¥4.84m1.1%
HK$ 72.6m
Lixin Tian
President10.9yrsCN¥2.14m0.27%
HK$ 18.0m
Lijun Tian
VP, Deputy Head of Medical Information Science Research Unit & Executive Director10.9yrsCN¥2.04m0.21%
HK$ 14.1m
Xin Zhou
VP & Executive Director6.3yrsCN¥673.00ksin datos
Richard L. Yeh
Independent Non-Executive Director3.8yrsCN¥120.00ksin datos
Eiji Tsuchiya
Non-Executive Director10.9yrssin datossin datos
Jun Ma
Independent Non-Executive Director3.8yrsCN¥120.00ksin datos
Shan Wang
Independent Non-Executive Director3.8yrsCN¥120.00ksin datos
Kazutaka Kanairo
Non-Executive Director1.6yrssin datossin datos

6.3yrs

Permanencia media

55yo

Promedio de edad

Junta con experiencia: La junta directiva de 2192 se considera experimentada (6.3 años de antigüedad promedio).